Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial - Top-Institutions - MDSpire

Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial

  • By

  • Zhiqiang Zhong

  • Hongjuan Lu

  • Ting Li

  • Lingying Ye

  • Ling Zhou

  • Xiaobing Wang

  • Xin Wu

  • Huji Xu

  • June 23, 2026

  • 0 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Shanghai Changzheng Hospital
    Shanghai Changzheng Hospital

    Shanghai, Shanghai

    Key Differentiators

    • Rheumatology

  • #2

    Swiss Clinical Quality Management
    Swiss Clinical Quality Management

    Zurich, Zurich

    Key Differentiators

    • Rheumatology

  • #3

    Ethics Commission of the Canton of Zurich
    Ethics Commission of the Canton of Zurich

    Zurich, Zurich

    Key Differentiators

    • Rheumatology

Original Source(s)

Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial

  • by Zhiqiang Zhong, Hongjuan Lu, Ting Li, Lingying Ye, Ling Zhou, Xiaobing Wang, Xin Wu, Huji Xu

  • June 23, 2026

Related Content

Healthcare utilization and costs in patients with rheumatoid arthritis using biologics or tofacitinib: a nationwide, population-based study

Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab

Restoring immune homeostasis in the spinal microenvironment: targeting mechano-inflammation and immunometabolic reprogramming